000			02320na a2200265 4500
999			_c3927 _d3927
003			PC3927
005			20200227133053.0
008			130622s2013 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aspa, eng
100			_aAndrés Belmonte, Amado _91321 _eNefrología
100			_aCalvo, Natividad _92625 _eNefrología
100			_aGonzález Monte, Esther _91487 _eNefrología
245			_aImpacto de darbepoetina alfa en el manejo de la anemia precoz postrasplante renal: estudio retrospectivo exploratorio. _h[artículo]
260			_b Nefrología : publicación oficial de la Sociedad Española Nefrologia, _c2013
300			_a33(1):107-15.
500			_aFormato Vancouver: Jiménez C, González E, Marqués M, Galeano C, Andrés A, Calvo N, Pascual J. Impacto de darbepoetina alfa en el manejo de la anemia precoz postrasplante renal: estudio retrospectivo exploratorio. Nefrologia. 2013 Jan 18;33(1):107-15.
501			_aPMID: 23364633
504			_aContiene 32 referencias
520			_aBackground and objectives: The use of darbepoetin alfa in the first week of post-renal transplant (RT). Methods: Retrospective observational study carried out in four hospitals, which included all adult patients that underwent RT for 9 months with haemoglobin data during the first 6 months of post-transplant (n = 129). Darbepoetina alfa was administered in accordance with the clinical practice. Results: darbepoetin alfa was administered in the first week to 60 individuals (46.5%), who had a mean baseline Hb (+/- standard deviation) of 12.7g/dl +/- 1.6g/dl. Anaemia incidence (Hb < 11g/dl) during the first month was higher in patients who did not receive darbepoetin alfa (40.6% vs. 25.0% in patients treated with darbepoetin alfa, P=.045). No anaemia incidence differences were observed during months +2 to +6. There was a tendency towards transfusion decrease in patients who received darbepoetin alfa (13.3% vs. 20.3%, P=.295). Renal recovery time was similar but in the subgroup which received grafts from donors with asystole there was a tendency towards a faster recovery with darbepoetin alfa (15.1 +/- 7.7 vs. 20.1 +/- 8.8 days, P=.157). The creatinine clearance rate at 3 and 6 months was similar. Fourteen patients (10.9%) suffered from cardiovascular events with no relation to darbepoetin alfa (P=.772). Conclusions: Administering darbepoetin alfa in the first week following renal transplant reduces anaemia incidence during the first month without increase cardiovascular events.
710			_986 _aServicio de Nefrología
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/3/pc3927.pdf _ySolicitar documento
942			_n0 _2ddc _cART